Use of celecoxib correlates with increased relative risk of acute pancreatitis: A case-control study in Taiwan

American Journal of Gastroenterology

Volumn 110, Issue 10, 2015, Pages 1490-1496

  Hung, Shih Chang ^a   Hung, Shih Rong ^b   Lin, Cheng Li ^c,d   Lai, Shih Wei ^c   Hung, Hung Chang ^a  

^a Nantou Hospital   (Taiwan)

^b Erlin Christian Hospital   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR;

ACUTE DISEASE; ADULT; AGED; ALCOHOL-RELATED DISORDERS; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CHOLELITHIASIS; COMORBIDITY; DIABETES MELLITUS; FACTUAL DATABASE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATITIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TAIWAN; VERY ELDERLY; YOUNG ADULT;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ALCOHOL-RELATED DISORDERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CELECOXIB; CHOLELITHIASIS; COMORBIDITY; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATITIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; YOUNG ADULT;

EID: 85027948543     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.259     Document Type: Article

References (33)

1. Gillon R. Medical ethics: four principles plus attention to scope. BMJ 1994;309:184-8.
2. Guideline for Good Clinical Practice International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use http://ichgcp.net/introduction 2002, Accessed 1 January 2015.
3. Schneeweiss S, Hasford J, Gottler M et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 2002;58:285-91.
4. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19.
5. Turk BG, Gunaydin A, Ertam I et al. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol 2013;32:41-5.
6. Lazzaroni M, Porro GB. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors. Drugs 2009;69:51-69.
7. Plantinga L, Grubbs V, Sarkar U et al. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med 2011;9:423-30.
8. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
9. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007;8:73.
10. Carrillo-Jimenez R, Nurnberger M. Celecoxib-induced acute pancreatitis and hepatitis: a case report. Arch Intern Med 2000;160:553-4.
11. Baciewicz AM, Sokos DR, King TJ. Acute pancreatitis associated with celecoxib. Ann Intern Med 2000;132:680.
12. Mennecier D, Ceppa F, Sinayoko L et al. Acute pancreatitis after treatment by celecoxib. Gastroenterol Clin Biol 2007;31:668-9.
13. Nind G, Selby W. Acute pancreatitis: a rare complication of celecoxib. Intern Med J 2002;32:624-5.
14. Lowenfels AB, Maisonneuve P, Sullivan T. The changing character of acute pancreatitis: epidemiology, aetiology, and prognosis. Curr Gastroenterol Rep 2009;11:97-103.
15. Yadav D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas 2006;33:323-30.
16. Hamada S, Masamune A, Kikuta K et al. Nationwide epidemiological survey of acute pancreatitis in Japan. Pancreas 2014;43:1244-8.
17. Nitsche C, Maertin S, Scheiber J et al. Drug-induced pancreatitis. Curr Gastroenterol Rep 2012;14:131-8.
18. Tenner S. Drug induced acute pancreatitis: does it exist? World J Gastroenterol 2014;20:16529-34.
19. Database NHIR. Taiwan http://nhird.nhri.org.tw/en/index.html Cited October 2014.
20. Lai SW, Liao KF, Liao CC et al. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore) 2010;89:295-9.
21. Lai SW, Muo CH, Liao KF et al. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol 2011;106:1697-704.
22. Hung SC, Liao KF, Lai SW et al. Risk factors associated with symptomatic cholelithiasis in Taiwan: a population-based study. BMC Gastroenterol 2011;11:111.
23. Liao KF, Lai SW, Li CI et al. Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol 2012;27:709-13.
24. Davies NM, McLachlan AJ, Day RO et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000;38:225-42.
25. Itthipanichpong C, Chompootaweep S, Wittayalertpanya S et al. Clinical pharmacokinetic of celecoxib in healthy Thai volunteers. J Med Assoc Thai 2005;88:632-8.
26. Blomgren KB, Sundstrom A, Steineck G et al. A Swedish case-control network for studies of drug-induced morbidity-acute pancreatitis. Eur J Clin Pharmacol 2002;58:275-83.
27. Sørensen HT, Jacobsen J, Norgaard M et al. Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment Pharmacol Ther 2006;24:111-6.
28. Gullo L, Migliori M, Olah A et al. Acute pancreatitis in five European countries: aetiology and mortality. Pancreas 2002;24:223-7.
29. Pezzilli R, Uomo G, Gabbrielli A et al. A prospective multicentre survey on the treatment of acute pancreatitis in Italy. Dig Liver Dis 2007;39:838-46.
30. Ince AT, Baysal B. Pathophysiology, classification and available guidelines of acute pancreatitis. Turk J Gastroenterol 2014;25:351-7.
31. Hammer HF. An update on pancreatic pathophysiology (do we have to rewrite pancreatic pathophysiology?). Wien Med Wochenschr 2014;164: 57-62.
32. Tenner S, Baillie J, DeWitt J et al. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol 2013;108:1400-15.
33. Premkumar R, Phillips AR, Petrov MS et al. The clinical relevance of obesity in acute pancreatitis: targeted systematic reviews. Pancreatology 2015;15:25-33.